123 related articles for article (PubMed ID: 20615083)
1. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Leuk Lymphoma; 2010 Sep; 51(9):1727-33. PubMed ID: 20615083
[TBL] [Abstract][Full Text] [Related]
2. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Int J Hematol; 2010 Jun; 91(5):792-8. PubMed ID: 20473593
[TBL] [Abstract][Full Text] [Related]
3. Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detection.
Belotti A; Elli E; Speranza T; Lanzi E; Pioltelli P; Pogliani E
Am J Hematol; 2012 Mar; 87(3):319-20. PubMed ID: 22190201
[TBL] [Abstract][Full Text] [Related]
4. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
6. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
Sultan S; Irfan SM
Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
[TBL] [Abstract][Full Text] [Related]
7. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM
Drug Des Devel Ther; 2015; 9():2687-94. PubMed ID: 26028965
[TBL] [Abstract][Full Text] [Related]
8. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
9. Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.
Treliński J; Chojnowski K; Cebula-Obrzut B; Smolewski P
Med Oncol; 2012 Dec; 29(4):2388-95. PubMed ID: 22418850
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.
Palandri F; Ottaviani E; Salmi F; Catani L; Polverelli N; Fiacchini M; Martinelli G; Baccarani M; Vianelli N
Leuk Lymphoma; 2009 Feb; 50(2):247-53. PubMed ID: 19235016
[TBL] [Abstract][Full Text] [Related]
11. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
12. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
13. Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.
Reményi G; Szász R; Debreceni IB; Szarvas M; Batár P; Nagy B; Kappelmayer J; Udvardy M
Platelets; 2013; 24(6):486-92. PubMed ID: 23216455
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
[TBL] [Abstract][Full Text] [Related]
15. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
[TBL] [Abstract][Full Text] [Related]
16. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
17. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
Falanga A; Marchetti M; Vignoli A; Balducci D; Russo L; Guerini V; Barbui T
Exp Hematol; 2007 May; 35(5):702-11. PubMed ID: 17577920
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
[TBL] [Abstract][Full Text] [Related]
19. Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia.
Gadomska G; Bartoszewska-Kubiak A; Boinska J; Matiakowska K; Ziołkowska K; Haus O; Rość D
Clin Appl Thromb Hemost; 2018 Oct; 24(7):1056-1060. PubMed ID: 29390868
[TBL] [Abstract][Full Text] [Related]
20. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
Lambert JR; Gale RE; Linch DC
Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
